AMRX Amneal Pharmaceuticals Inc. Class A

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Amneal to Report Third Quarter 2025 Results on October 30, 2025

BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.

The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at . Individuals may register for the webcast by clicking the link . To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this . The access code for the call is 272787. A replay of the conference call will be posted shortly after the call.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit  and follow us on .

Investor Contact

Anthony DiMeo

VP, Investor Relations



EN
30/09/2025

Underlying

AMRXAmneal Pharmaceuticals Inc. Class A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amneal Pharmaceuticals Inc. Class A

 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single-...

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilize...

December 9, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREX...

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapiesCREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided a longer duration of benefit with each doseFindings highlight CREXONT as a key therapy in a category with limited innovationELEVATE-PD study is ongoing with longer-term data expected in 2026 BRIDGEWATER, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”...

December 5, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal to Participate in Upcoming Investor Conferences

Amneal to Participate in Upcoming Investor Conferences BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial Officer, will participate in following upcoming investor conferences: Piper Sandler 2025 Healthcare ConferenceDate: December 3, 2025Fireside Chat: Wednesday, December 3, 2025, at 9:30AM ESTLocation: New York, NY J.P. Morgan 2026 Healthcare ConferenceDate: January 12-15, 2026Presentation: Tuesday, January 13, 2026, at 4:30PM PSTLocati...

December 2, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aer...

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol Represents second complex respiratory therapeutic product approval in Q4 2025 BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s albuterol sulfate inhalation aerosol (90 mcg per actuation). The product is the generic equivalent of PROAIR® HFA (albuterol sulfate inhalation aerosol), a registered trademark of Teva Respiratory LLC. This approval foll...

December 2, 2025 1 EN
 PRESS RELEASE
Free
AMRX Amneal Pharmace...

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion...

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026  BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of ...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch